Recommendations for the registration of agents for prevention and treatment of glucocorticoid-induced osteoporosis: an update from the Group for the Respect of Ethics and Excellence in Science

Osteoporosis International, Mar 2009

J. Compston, D. M. Reid, J. Boisdron, M.-L. Brandi, N. Burlet, D. Cahall, P. D. Delmas, W. Dere, J.-P. Devogelaer, L. A. Fitzpatrick, et al.

A PDF file should load here. If you do not see its contents the file may be temporarily unavailable at the journal website or you do not have a PDF plug-in installed and enabled in your browser.

Alternatively, you can download the file locally and open with any standalone PDF reader:

http://link.springer.com/content/pdf/10.1007%2Fs00198-008-0735-7.pdf

Recommendations for the registration of agents for prevention and treatment of glucocorticoid-induced osteoporosis: an update from the Group for the Respect of Ethics and Excellence in Science

J. Compston 0 1 2 3 4 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 D. M. Reid 0 1 2 3 4 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 J. Boisdron 0 1 2 3 4 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 M.-L. Brandi 0 1 2 3 4 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 N. Burlet 0 1 2 3 4 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 D. Cahall 0 1 2 3 4 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 P. D. Delmas 0 1 2 3 4 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 W. Dere 0 1 2 3 4 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 N. Goel 0 1 2 3 4 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 S. Korte 0 1 2 3 4 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 A. Laslop 0 1 2 3 4 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 B. Mitlak 0 1 2 3 4 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 S. Ormarsdottir 0 1 2 3 4 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 J. Ringe 0 1 2 3 4 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 R. Rizzoli 0 1 2 3 4 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 Y. Tsouderos 0 1 2 3 4 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 T. Van Staa 0 1 2 3 4 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 J.-Y. Reginster 0 1 2 3 4 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 Erratum to: Osteoporos Int 0 1 2 3 4 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 D. Cahall 0 1 2 3 4 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 was incorrectly given as Cincinnati 0 1 2 3 4 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 USA. The 0 1 2 3 4 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 0 B. Flamion Laboratory of Physiology and Pharmacology, University of Namur , Namur, Belgium 1 D. M. Reid University of Aberdeen Medical School , Foresterhill, Aberdeen AB25 2ZD, UK 2 L. A. Fitzpatrick Medicines Disease Center , GlaxoSmithKline, King of Prussia, PA, USA 3 true location is Bridgewater, NJ, USA 4 N. Goel Clinical Development , UCB Inc., Smyrna, GA, USA 5 ) Department of Medicine, University of Cambridge School of Clinical Medicine , Cambridge, UK 6 J.-P. Devogelaer The Arthritis Unit, Universit Catholique de Louvain , Brussels, Belgium 7 W. Dere Amgen, Thousand Oaks, CA, USA 8 P. D. Delmas Department of Medicine, University of Lyon and INSERM Research Unit 831 , Lyon, France 9 D. Cahall Sanofi-Aventis, Bridgewater, NJ, USA 10 N. Burlet International Osteoporosis Foundation , Nyon, Switzerland 11 M.-L. Brandi Metabolic Bone Unit, Laboratory of Molecular Genetics, Department of Internal Medicine, University of Florence , Florence, Italy 12 J. Boisdron Hoffman-La Roche Ltd, Basle, Switzerland 13 B. Mitlak Lilly Research Laboratories , Eli Lilly and Company, Indianapolis, IN, USA 14 A. Laslop AGES PharmMed, Vienna, Austria 15 S. Korte Novartis Pharma, Berne, AG, Switzerland 16 J.-Y. Reginster Department of Public Health Sciences, University of Lige , Lige, Belgium , Chairman GREES, Lige, Belgium 17 J. Ringe West German Osteoporosis Center (WOZ) and Med. Clinic 4 at Klinikum Leverkusen , Univerity of Cologne, Cologne, Germany 18 T. Van Staa General Practice Research Database, Medicines and Healthcare Products Regulatory Agency , London, UK 19 Y. Tsouderos Institut de Recherches Internationales Servier , Courbevoie, France 20 R. Rizzoli Division of Bone Diseases, WHO Collaborating Centre for Osteoporosis Prevention, Department of Rehabilitation and Geriatrics, Geneva University Hospitals and Faculty of Medicine , Geneva, Switzerland 21 S. Ormarsdottir Icelandic Medicines Control Agency , Seltjarnarnes, Iceland


This is a preview of a remote PDF: http://link.springer.com/content/pdf/10.1007%2Fs00198-008-0735-7.pdf

J. Compston, D. M. Reid, J. Boisdron, M.-L. Brandi, N. Burlet, D. Cahall, P. D. Delmas, W. Dere, J.-P. Devogelaer, L. A. Fitzpatrick, B. Flamion, N. Goel, S. Korte, A. Laslop, B. Mitlak, S. Ormarsdottir, J. Ringe, R. Rizzoli, Y. Tsouderos, T. Van Staa, J.-Y. Reginster. Recommendations for the registration of agents for prevention and treatment of glucocorticoid-induced osteoporosis: an update from the Group for the Respect of Ethics and Excellence in Science, Osteoporosis International, 2009, 497-498, DOI: 10.1007/s00198-008-0735-7